Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Acetyl L-carnitine (ALC) has been investigated as a potential treatment for Attention Deficit Disorder (ADD/ADHD), particularly in children and adolescents. The rationale stems from ALC’s role in brain metabolism, neurotransmitter modulation (especially acetylcholine and dopamine), and its potential neuroprotective effects. Several randomized controlled trials and meta-analyses have evaluated its efficacy.

Some clinical trials have demonstrated mild to moderate benefits of ALC supplementation in reducing ADHD symptoms, especially in subgroups such as children with the inattentive subtype or those carrying specific genetic markers (for example, the dopamine transporter gene DAT1 10-repeat allele). However, other studies have failed to show significant improvement compared to placebo. A 2012 meta-analysis concluded that while ALC is generally safe and well-tolerated, its overall efficacy for ADHD is modest at best, with inconsistent results across studies.

ALC is not a first-line or widely endorsed treatment for ADD/ADHD, and current clinical guidelines do not recommend it over established pharmacological therapies. Nonetheless, its favorable safety profile and some positive findings in subpopulations have led to continued research interest. In summary, while there is some scientific evidence supporting its use for ADD/ADHD—especially as an adjunct or in specific cases—the evidence is not strong or consistent enough to warrant broad clinical recommendation.

More about acetyl l-carnitine
More about Attention Deficit Disorder

Other ingredients used for Attention Deficit Disorder

Other health conditions supported by acetyl l-carnitine

Products containing acetyl l-carnitine

Nature's Sunshine Solstic Cardio